Houston VA begins clinical trial for COVID-19 treatment

Tocilizumab (TCZ) — for Veterans with COVID-19 severe pneumonia


shadow

In early July, the Michael E. DeBakey VA Medical Center became the first VA facility to participate in an international clinical trial evaluating the therapeutic benefit of an immunomodulator drug, Tocilizumab (TCZ), as a treatment for Veterans with COVID-19 severe pneumonia.

“COVID-19 is known to cause extensive damage in the lungs,” said Dr. Lavannya Pandit, a Houston VA pulmonologist and critical care physician who is a co-investigator in the study. “This often leads to difficulty breathing and, eventually, pneumonia. Pneumonia triggers a hyperimmune response that we are seeing can be more detrimental to some patients than the original infection.”

Medical personnel have used TCZ successfully to treat hyperimmune responses in cancer patients. The trial results will help determine if TCZ has a similar effect in patients who are diagnosed with severe COVID-19 pneumonia.

The clinical trial is a randomized, placebo-controlled study. Both the investigator and participant are blinded to who is receiving the TCZ treatment. Eligible participants are patients who are in the hospital and who chest imaging has confirmed has severe COVID-19 pneumonia.

Veterans at Houston VA very willing to step up

Medical personnel will monitor Veterans in a clinical environment for their responses to the treatment. Responses may include disease progression, the duration of hospitalization and the need for critical care and other supportive treatments.

“VA offers cutting-edge treatments and top quality care for Veterans with COVID-19,” said Dr. Barbara Trautner. Trautner is a faculty member at the Behavioral Health Program, Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center.

“Participating in this clinical trial allows our Veterans the opportunity to contribute to scientific progress,” she said. “So far, Veterans at the Houston VA have been very willing to step up and volunteer. We enrolled eight Veterans in the first three days of the study.”

Trial taking place in more than 50 locations

“The treatments we offer for COVID-19 three months from now will be very different than what we offer today because of scientific trials like this,” said Trautner.

In addition to Houston VA, the trial is taking place in more than 50 locations across the United States, Europe and Canada, including at the Baylor College of Medicine.

“I always find it an honor and privilege to care for our Veterans who have served our country,” Trautner said. “The Veterans we are enrolling in this study are eager to join the fight against COVID-19, and we are happy to provide them this opportunity and do our part.”


Maureen Dyman is a public affairs officer at the Michael E. DeBakey VA Medical Center in Houston.

Author

VAntagePoint Contributor

— VAntage Point Contributors provide insight and perspective on a wide range of Veterans issues. If you’d like to contribute a story to VAntage Point, learn how you can submit a guest blog at http://www.blogs.va.gov/VAntage/how-to-submit-a-guest-post/

Comments

  1. Maria R. Appleby    

    When the study is complete, will the VA publish a press release about it, or will the findings be published in a medical journal? I’d be interested in finding out how it all turned out.

Comments are closed.